This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
Based on a post hoc analysis, fewer required respiratory interventions
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately US $ 260.2 million
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Subscribe To Our Newsletter & Stay Updated
